{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T14:26:34Z","timestamp":1780323994892,"version":"3.54.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T00:00:00Z","timestamp":1704672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T00:00:00Z","timestamp":1704672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Data about biosimilar Peg-filgrastim (bioPEG) in autologous stem cell transplant (ASCT) are still scarce. The aim of this study has been to assess efficacy and safety of bioPEG among lymphoma and myeloma patients undergoing ASCT, comparing these data with historical controls receiving other G-CSFs. Furthermore, an economic evaluation has been included to estimate the savings by using bioPEG. This is a prospective cohort study comparing lymphoma and myeloma patients undergoing ASCT and receiving bioPEG (<jats:italic>n<\/jats:italic>\u2009=\u200973) with three historical consecutive cohorts collected retrospectively who received other G-CSFs (Lenograstim \u2014 Leno \u2014 <jats:italic>n<\/jats:italic>\u2009=\u2009101, biosimilar Filgrastim \u2014 bioFIL <jats:italic>n<\/jats:italic>\u2009=\u2009392, and originator Peg-filgrastim \u2014 oriPEG <jats:italic>n<\/jats:italic>\u2009=\u200960). We observed a significantly shorter time to neutrophils and platelet engraftment (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) in patients treated with bioPEG and oriPEG. Moreover, patients who received bioPEG showed a shorter hospitalization time (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and a lower transfusion need (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). We did not observe any significant difference in terms of transplant-related mortality, mucositis, and diarrhea among the four groups. No serious adverse events were associated with bioPEG. Similar data were obtained after running a stratified analysis for lymphomas and myeloma separately conducted by using a propensity score matching. The average total cost per patient of bioPEG was \u20ac 18218.9 compared to \u20ac 23707.8, \u20ac 20677.3 and \u20ac 19754.9 of Leno, oriPEG, and bioFIL, respectively. In conclusion, bioPEG seems to be as effective as the originator and more effective than short-acting G-CSFs in terms of post-transplant engraftment in myeloma and lymphoma patients undergoing ASCT. Moreover, bioPEG was cost-effective when compared with the other G-CSFs.<\/jats:p>","DOI":"10.1007\/s00277-023-05604-9","type":"journal-article","created":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T11:03:07Z","timestamp":1704711787000},"page":"947-956","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and safety of biosimilar Peg-filgrastim after autologous stem cell transplant in myeloma and lymphoma patients: a comparative study with biosimilar Filgrastim, Lenograstim, and originator Peg-filgrastim"],"prefix":"10.1007","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6353-2272","authenticated-orcid":false,"given":"Francesco","family":"Marchesi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Terrenato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Papa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Tomassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Falcucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svitlana","family":"Gumenyuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Palombi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Pisani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Renzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atelda","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Spadea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Regazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Giulia","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mafalda","family":"De Rienzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Ripellino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Sgromo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Viggiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Ponte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramy","family":"Kayal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iole","family":"Cordone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Laura","family":"Foddai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Mengarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,8]]},"reference":[{"key":"5604_CR1","unstructured":"Auletta JJ, Kou J, Chen M, Shaw BE (2021) Current use and outcome of hematopoietic stem cell transplantation: CIBMTR US summary slides. https:\/\/www.cibmtr.org\/ReferenceCenter\/SlidesReports\/SummarySlides\/pages\/index.aspx. Assessed Aug 31 2023"},{"key":"5604_CR2","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1038\/s41409-022-01691-w","volume":"57","author":"JA Snowden","year":"2022","unstructured":"Snowden JA, S\u00e1nchez-Ortega I, Corbacioglu S et al (2022) Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transplant 57:1217\u20131239","journal-title":"Bone Marrow Transplant"},{"key":"5604_CR3","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.clml.2015.02.024","volume":"15","author":"VR Bhatt","year":"2015","unstructured":"Bhatt VR, Loberiza FR Jr, Jing H et al (2015) Mortality patterns among recipients of autologous hematopoietic stem cell transplantation for lymphoma and myeloma in the past three decades. Clin Lymphoma Myeloma Leuk 15:409-415.e1","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"5604_CR4","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.critrevonc.2017.11.005","volume":"120","author":"Y Lalami","year":"2017","unstructured":"Lalami Y, Klastersky J (2017) Impact of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) on cancer treatment outcomes: an overview about well-established and recently emerging clinical data. Crit Rev Oncol Hematol 120:163\u2013179","journal-title":"Crit Rev Oncol Hematol"},{"key":"5604_CR5","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.2174\/0929867323666160517115907","volume":"23","author":"F Marchesi","year":"2016","unstructured":"Marchesi F, Mengarelli A (2016) Biosimilar filgrastim in autologous peripheral blood hematopoietic stem cell mobilization and post-transplant hematologic recovery. Curr Med Chem 23:2217\u20132229","journal-title":"Curr Med Chem"},{"key":"5604_CR6","doi-asserted-by":"publisher","first-page":"5111","DOI":"10.1182\/blood-2012-04-425744","volume":"120","author":"M Weise","year":"2012","unstructured":"Weise M, Bielsky MC, De Smet K et al (2012) Biosimilars: what clinicians should know. Blood 120:5111\u20135117","journal-title":"Blood"},{"key":"5604_CR7","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/clpt.2011.343","volume":"91","author":"M McCamish","year":"2012","unstructured":"McCamish M, Woollett G (2012) The state of art in the development of biosimilars. Clin Pharmacol Ther 91:405\u2013417","journal-title":"Clin Pharmacol Ther"},{"key":"5604_CR8","unstructured":"U.S. Food and Drug Administration (2017) Biosimilar and interchangeable products. https:\/\/www.fda.gov\/drugs\/biosimilars\/biosimilar-and-interchangeable-products"},{"issue":"Suppl. 1","key":"5604_CR9","doi-asserted-by":"publisher","first-page":"S103","DOI":"10.1016\/j.jval.2018.04.700","volume":"21","author":"E Heredia","year":"2018","unstructured":"Heredia E, Ribeiro A (2018) Discount offered by first and subsequent biosimilars in the US, EU and LATAM: impact trends of originator starting price, market dynamics and regulations. Value Health 21(Suppl. 1):S103\u2013S104","journal-title":"Value Health"},{"key":"5604_CR10","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s40259-019-00395-w","volume":"34","author":"B Dutta","year":"2020","unstructured":"Dutta B, Huys I, Vulto AG et al (2020) Identifying key benefits in European off-patent biologics and biosimilar markets: it is not only about price! BioDrugs 34:159\u2013170","journal-title":"BioDrugs"},{"key":"5604_CR11","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1007\/s00277-023-05228-z","volume":"102","author":"M Martino","year":"2023","unstructured":"Martino M, Gori M, Porto G et al (2023) Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high-dose melphalan and autologous stem cell transplantation. Ann Hematol 102:1915\u20131925","journal-title":"Ann Hematol"},{"key":"5604_CR12","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.3324\/haematol.2013.091025","volume":"98","author":"D Averbuch","year":"2013","unstructured":"Averbuch D, Orasch C, Cordonnier C et al (2013) ECIL4, a joint venture of EBMT, EORTC, ICHS, ESGICH\/ESCMID and ELN. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European conference on infections in leukemia. Haematologica 98:1826\u20131835","journal-title":"Haematologica"},{"key":"5604_CR13","doi-asserted-by":"publisher","first-page":"882","DOI":"10.6004\/jnccn.2016.0093","volume":"14","author":"LR Baden","year":"2016","unstructured":"Baden LR, Swaminathan S, Angarone M et al (2016) Prevention and treatment of cancer-related infections, version 2.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 14:882\u2013913","journal-title":"J Natl Compr Canc Netw"},{"key":"5604_CR14","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1002\/sim.4200","volume":"30","author":"PC Austin","year":"2011","unstructured":"Austin PC (2011) Comparing paired vs non-paired statistical methods of analyses when making inference about absolute risk reduction in propensity score matched samples. Stat Med 30:1292\u20131301","journal-title":"Stat Med"},{"key":"5604_CR15","unstructured":"Accordo interregionale per la compensazione della mobilit\u00e0 sanitaria (2020) Emocomponenti ad uso trasfusionale (1 unit\u00e0), Italy, cod. 99758, 99766"},{"key":"5604_CR16","unstructured":"Italia Ministero dell\u2019Economia e delle Finanze; Commissione Tecnica per la Finanza Pubblica. Libro Verde Sulla Spesa Pubblica. Spendere Meglio: Alcune Prime Indicazioni; Ministero dell\u2019Economia e delle Finanze (2007) Roma, Italy, pp 36\u201357."},{"key":"5604_CR17","doi-asserted-by":"publisher","first-page":"436","DOI":"10.3109\/10428194.2010.545462","volume":"52","author":"L Wannesson","year":"2011","unstructured":"Wannesson L, Luthi F, Zucca E et al (2011) Pegfilgrastim to accelerate neutrophil engraftment following peripheral blood stem cell transplant and reduce the duration of neutropenia, hospitalization, and use of intravenous antibiotics: a phase II study in multiple myeloma and lymphoma and comparison with filgrastim-treated matched controls. Leuk Lymphoma 52:436\u2013443","journal-title":"Leuk Lymphoma"},{"key":"5604_CR18","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/bjh.13199","volume":"169","author":"F Marchesi","year":"2015","unstructured":"Marchesi F, Cerchiara E, Dessanti ML et al (2015) Comparison between biosimilar vs other granulocyte-colony stimulating factor formulations (originator filgrastim, peg-filgrastim and lenograstim) after autologous stem cell transplantation: a retrospective survey from the Rome Transplant Network. Br J Haematol 169:293\u2013296","journal-title":"Br J Haematol"},{"key":"5604_CR19","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.exphem.2005.11.013","volume":"34","author":"G Vanstraelen","year":"2006","unstructured":"Vanstraelen G, Frere P, Ngirabacu MC et al (2006) Pegfilgrastim compared with filgrastim after autologous hematopoietic peripheral blood stem cell transplantation. Exp Hematol 34:382\u2013388","journal-title":"Exp Hematol"},{"key":"5604_CR20","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1111\/bcp.14226","volume":"86","author":"A Bellon","year":"2020","unstructured":"Bellon A, Wang J, Skerjanec A et al (2020) A large multicenter, randomized, double-blind, cross-over study in healthy volunteers to compare pharmacokinetics, pharmacodynamics and safety of a pegfilgrastim biosimilar with its US- and EU-reference biologics. Br J Clin Pharmacol 86:1139\u20131149","journal-title":"Br J Clin Pharmacol"},{"key":"5604_CR21","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1080\/16078454.2021.2003071","volume":"26","author":"X Wang","year":"2021","unstructured":"Wang X, Ren J, Liang X, He P (2021) Efficacy and cost of G-CSF derivatives for prophylaxis of febrile neutropenia in lymphoma and multiple myeloma patients underwent autologous hematopoietic stem cell transplantation. Hematology 26:950\u2013955","journal-title":"Hematology"},{"key":"5604_CR22","first-page":"A918","volume":"100","author":"RC Allen","year":"2002","unstructured":"Allen RC (2002) Ex vivo half-life of neutrophils from healthy human subjects pre and post treatment with daily filgrastim or single-dose pegfilgrastim. Blood 100:A918","journal-title":"Blood"},{"key":"5604_CR23","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.2174\/1381612043452613","volume":"10","author":"G Molineux","year":"2004","unstructured":"Molineux G (2004) The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta). Curr Pharm Des 10:1235\u20131244","journal-title":"Curr Pharm Des"},{"key":"5604_CR24","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2165\/11586040-000000000-00000","volume":"50","author":"BB Yang","year":"2011","unstructured":"Yang BB, Kido A (2011) Pharmacokinetics and pharmacodynamics of pegfilgrastim. Clin Pharmacokinet 50:295\u2013306","journal-title":"Clin Pharmacokinet"},{"key":"5604_CR25","doi-asserted-by":"publisher","first-page":"34","DOI":"10.5001\/omj.2019.06","volume":"34","author":"MN Hassan","year":"2019","unstructured":"Hassan MN, Fauzi HM, Husin A et al (2019) Autologous peripheral blood stem cell transplantation among lymphoproliferative disease patients: factors influencing engraftment. Oman Med J 34:34\u201343","journal-title":"Oman Med J"},{"key":"5604_CR26","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1186\/1471-2407-11-404","volume":"11","author":"KL Cooper","year":"2011","unstructured":"Cooper KL, Madan J, Whyte S et al (2011) Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer 11:404","journal-title":"BMC Cancer"},{"key":"5604_CR27","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s00520-014-2457-z","volume":"23","author":"AM Pfeil","year":"2015","unstructured":"Pfeil AM, Allcott K, Pettengell R et al (2015) Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review. Sup Care Cancer 23:525\u2013545","journal-title":"Sup Care Cancer"},{"key":"5604_CR28","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1093\/annonc\/mdp576","volume":"21","author":"L Castagna","year":"2010","unstructured":"Castagna L, Bramanti S, Levis A et al (2010) Pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous peripheral blood stem cell support. Ann Oncol 21:1482\u20131485","journal-title":"Ann Oncol"},{"key":"5604_CR29","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/bmt.2016.207","volume":"52","author":"F Marchesi","year":"2017","unstructured":"Marchesi F, Tendas A, Giannarelli D et al (2017) Cryotherapy reduces oral mucositis and febrile episodes in myeloma patients treated with high-dose melphalan and autologous stem cell transplant: a prospective, randomized study. Bone Marrow Transplant 52:154\u2013156","journal-title":"Bone Marrow Transplant"},{"key":"5604_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2021.11.009","volume":"52","author":"TK Kvien","year":"2022","unstructured":"Kvien TK, Patel K, Strand V (2022) The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems. Semin Arthritis Rheum 52:151939","journal-title":"Semin Arthritis Rheum"},{"issue":"16 Suppl","key":"5604_CR31","first-page":"s331","volume":"21","author":"SC Singh","year":"2015","unstructured":"Singh SC, Bagnato KM (2015) The economic implications of biosimilars. Am J Manag Care 21(16 Suppl):s331-340","journal-title":"Am J Manag Care"},{"key":"5604_CR32","doi-asserted-by":"publisher","first-page":"1739509","DOI":"10.1080\/20016689.2020.1739509","volume":"8","author":"E Moorkens","year":"2020","unstructured":"Moorkens E, Broux H, Huys I et al (2020) Economic evaluation of biosimilars for reimbursement purposes - what, when, how? J Mark Access Health Policy 8:1739509","journal-title":"J Mark Access Health Policy"},{"key":"5604_CR33","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1007\/s00520-013-1911-7","volume":"21","author":"P Gasc\u00f3n","year":"2013","unstructured":"Gasc\u00f3n P, Tesch H, Verpoort K et al (2013) Clinical experience with Zarzio\u00ae in Europe: what have we learned? Support Care Cancer 21:2925\u20132932","journal-title":"Support Care Cancer"},{"key":"5604_CR34","first-page":"976","volume":"24","author":"LS Schwartzberg","year":"2018","unstructured":"Schwartzberg LS, Lal LS, Balu S et al (2018) Clinical outcomes of treatment with filgrastim versus a filgrastim biosimilar and febrile neutropenia-associated costs among patients with nonmyeloid cancer undergoing chemotherapy. J Manag Care Spec Pharm 24:976\u2013984","journal-title":"J Manag Care Spec Pharm"},{"key":"5604_CR35","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s40259-020-00411-4","volume":"34","author":"P Cornes","year":"2020","unstructured":"Cornes P, Gascon P, Vulto AG et al (2020) Biosimilar pegfilgrastim: improving access and optimising practice to supportive care that enables cure. BioDrugs 34:255\u2013263","journal-title":"BioDrugs"},{"key":"5604_CR36","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1177\/1078155220962208","volume":"27","author":"PR Tilleul","year":"2021","unstructured":"Tilleul PR, Rodgers-Gray BS, Edwards JO (2021) Introduction of biosimilar pegfilgrastim in France: economic analysis of switching from originator. J Oncol Pharm Pract 27:1604\u20131615","journal-title":"J Oncol Pharm Pract"},{"key":"5604_CR37","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ejca.2020.07.037","volume":"139","author":"K H\u00fcbel","year":"2020","unstructured":"H\u00fcbel K, Kron F, Lux MP (2020) Biosimilars in oncology: effects on economy and therapeutic innovations. Eur J Cancer 139:10\u201319","journal-title":"Eur J Cancer"},{"key":"5604_CR38","doi-asserted-by":"publisher","unstructured":"Cornes P, Kelton J, Liu R et al (2022) Real-world cost-effectiveness of primary prophylaxis with G-CSF biosimilars in patients at intermediate\/high risk of febrile neutropenia. Future Oncol. https:\/\/doi.org\/10.2217\/fon-2022-0095","DOI":"10.2217\/fon-2022-0095"},{"key":"5604_CR39","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1093\/annonc\/mdx303","volume":"28","author":"K Blackwell","year":"2017","unstructured":"Blackwell K, Gascon P, Jones CM et al (2017) Pooled analysis of two randomized, double blind trials comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer. Ann Oncol 28:2272\u20132277","journal-title":"Ann Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05604-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05604-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05604-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T10:06:33Z","timestamp":1707905193000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05604-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,8]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["5604"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05604-9","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,8]]},"assertion":[{"value":"17 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the local institutional review board and ethical committee (approval protocol number: 36\/IRE\/23\u20132866) and conducted in accordance to the Helsinki Declaration and the International Conference on Harmonization Guidelines for Good Clinical Practice. All patients had signed a specific informed consent for conditioning chemotherapy, for transplant and for data analysis for scientific purposes.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}